Share Price:

APNASPENAspen Pharmacare Hldgs17545595 (3.51%)
Our Response to Covid
Country Sites

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Day: November 26, 2018

Aspen launches novel ARV Combination: Set to further improve treatment options

Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option. EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will… Continue reading Aspen launches novel ARV Combination: Set to further improve treatment options

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.